One A Day Marketing Claims Spark Another CSPI-Bayer Face Off
This article was originally published in The Tan Sheet
Executive Summary
The Center for Science in the Public Interest threatens to sue if Bayer HealthCare does not discontinue claims that One A Day multivitamins “support” breast, heart, eye and bone health. CSPI argues the problem is rooted in linking legitimate claims to scientific research in a way that implies disease claims.
You may also be interested in...
CSPI Litigation Again Targets Bayer One A Day Claims
The proposed class-action complaint CSPI filed federal court marks the consumer advocacy group’s third allegation against claims for One A Day products. The complaint seeks an injunction against some claims and refunds to consumers who “purchased the products expecting the promised benefits,” CSPI says.
CSPI Litigation Again Targets Bayer One A Day Claims
The proposed class-action complaint CSPI filed federal court marks the consumer advocacy group’s third allegation against claims for One A Day products. The complaint seeks an injunction against some claims and refunds to consumers who “purchased the products expecting the promised benefits,” CSPI says.
Bayer Says One A Day Selenium Prostate Cancer Claims Are In Fair Play
Bayer asserts the prostate cancer risk reduction claims for its One A Day Men's multivitamin supplements are backed by an FDA-approved qualified health claim for selenium